Search for a trial

Gastrointestinal stromal tumors: assessment of mutations in tumors and in circulating tumor DNA and measurement of TKI plasma exposure to optimize treatment

Primary objectives:• To assess whether secondary GIST mutations can be found in circulating tumor DNA of patients with progressive disease on TKI treatment (according to RECIST 1.1 on computer tomography), whereas they are NOT present in the…

A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer*s disease; part II: open-label extension for participating patients

The primary efficacy objective for this study was to evaluate the efficacy of gantenerumab compared with placebo administered to patients by subcutaneous (SC) injection over 100 weeks as measured by the following co-primary endpoints (final outcome…

Fixation of the Simpliciti stemless humeral component, a radio-stereophotogrammatic analysis

Primary objective:Identifying the fixation and migration patterns of the Simplicity (Tornier, France) stem less humeral component in vivo, using model based radiostereophotogrammetric (mRSA) analysis.Secondary objective:To evaluate the mid and long…

A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)

This study has been transitioned to CTIS with ID 2024-512358-78-00 check the CTIS register for the current data. Part 1 of the trial (already completed):The primary objective of the research concerned the determination of the Maximum Tolerated Dose…

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination with Obinutuzumab (GA101) in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin*s Lymphoma

Primary Objectives:• Determine the safety and tolerability of CC-122 administered in combination with obinutuzumab.• Determine the non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of CC-122 administered in…